logo

Portola Pharmaceuticals Inc. (PTLA)



Trade PTLA now with
  Date
  Headline
10/28/2019 9:10:28 AM Portola Says Effective Hemostasis Achieved In 82% Of Evaluable Patients With Acute Gastrointestinal Bleeding
9/19/2019 8:21:53 AM Portola Pharma Appoints Ted Love To Board
8/12/2019 4:49:06 PM Portola Pharmaceuticals Announces Proposed Offering Of Common Stock
8/6/2019 8:32:42 AM Portola Launches European Sales Of Ondexxya With First Orders In Europe
7/8/2019 8:35:42 AM Portola : Vitro Data Shows 4F-PCCs No Direct Effect On Inhibition Of Thrombin Generation By Factor Xa Inhibitors
6/17/2019 7:52:17 AM William Blair Reiterates Portola Pharmaceuticals Inc. (PTLA) At Outperform
1/28/2019 9:23:57 AM Portola Appoints Sheldon Koenig As EVP And Chief Commercial Officer
12/31/2018 3:44:14 PM FDA OKs Portola Pharma's Approval Supplement For Andexxa Generation 2 Manufacturing Process
12/14/2018 7:18:22 AM William Blair Reiterates Portola Pharmaceuticals Inc. (PTLA) At Outperform
12/12/2018 7:54:01 AM William Blair Reiterates Portola Pharmaceuticals Inc. (PTLA) At Outperform
12/11/2018 7:03:46 AM CHMP Extends Review Period For Portola Pharmaceuticals’ Ondexxya To February 28, 2019
12/3/2018 9:32:06 PM Portola Updates Interim Results From Ongoing Phase 2a Study Of Cerdulatinib
9/20/2018 8:32:59 AM Portola Pharma Names Scott Garland President And CEO
9/7/2018 8:34:26 AM Portola Pharma Chief Commercial Officer Tao Fu To Resign, Effective Sept. 21
8/31/2018 8:32:44 AM Portola Submits Prior Approval Supplement To FDA For Large-Scale Generation 2 Andexxa Process
  
 
>